Table 2.

Summary of TEAEs by Treatment and Dose (Safety Population)

	Placebo	navafenterol 50 μg	navafenterol 200 μg	navafenterol 400 μg	navafenterol 900 μg	navafenterol 1800 μg	navafenterol 2100 μg	Overall
N	12	6	6	6	6	6	5	16
Any TEAE, n (%)	7 (58.3)	5 (83.3)	5 (83.3)	3 (50.0)	3 (50.0)	3 (50.0)	2 (40.0)	14 (87.5)
Most common TEAEs, n (%)a
Headache	3 (25.0)	3 (50.0)	1 (16.7)	2 (33.3)	2 (33.3)	1 (16.7)	0	10 (62.5)
Nasopharyngitis	1 (8.3)	3 (50.0)	1 (16.7)	0	0	0	2 (40.0)	7 (43.8)
Chest discomfort	1 (8.3)	1 (16.7)	1 (16.7)	0	0	0	0	3 (18.8)
Skin irritation	0	1 (16.7)	1 (16.7)	0	0	1 (16.7)	0	3 (18.8)
Wheezing	1 (8.3)	1 (16.7)	1 (16.7)	0	0	0	0	3 (18.8)
Cough	0	1 (16.7)	0	0	1 (16.7)	0	0	2 (12.5)
Dizziness	1 (8.3)	0	1 (16.7)	0	0	0	0	2 (12.5)
Feeling hot	0	1 (16.7)	0	0	0	0	1 (20.0)	2 (12.5)
Nausea	0	1 (16.7)	0	0	1 (16.7)	0	0	2 (12.5)

TEAE treatment-emergent adverse event

Adverse events were coded using Medical Dictionary for Regulatory Activities version 18.1

^aMost common TEAEs reported by ≥2 patients overall